계명대학교 의학도서관 Repository

Ramosetron versus Palonosetron in Combination with Aprepitant and Dexamethasone for the Control of Highly-Emetogenic Chemotherapy-Induced Nausea and Vomiting

Metadata Downloads
Author(s)
Jin Hyoung KangJung Hye KwonYun-Gyoo LeeKeon Uk ParkHo Jung AnJoohyuk SohnYoung Mi SeolHyunwoo LeeHwan-Jung YunJin Seok AhnJi Hyun YangHunho SongDong-Hoe KooJin Young KimGun Min KimHwa Jung Kim
Keimyung Author(s)
Park, Keon UkKim, Jin Young
Department
Dept. of Internal Medicine (내과학)
Journal Title
Cancer Research and Treatment
Issued Date
2020
Volume
52
Issue
3
Keyword
RamosetronPalonosetronAprepitantAntiemeticsNauseaVomitingNeoplasms
Abstract
Purpose:
The purpose of this study was to compare ramosetron (RAM), aprepitant (APR), and dexamethasone (DEX) [RAD] with palonosetron (PAL), APR, and DEX [PAD] in controlling highly-emetogenic chemotherapy (HEC)–induced nausea and vomiting.

Materials and Methods:
Patients were randomly assigned (1:1) to receive RAD or PAD:RAM (0.3 mg intravenously) or PAL (0.25 mg intravenously) D1, combined with APR (125 mg orally, D1 and 80 mg orally, D2-3) and DEX (12 mg orally or intravenously, D1 and 8 mg orally, D2-4). Patients were stratified by sex, cisplatin-based chemotherapy, and administration schedule. The primary endpoint was overall complete response (CR), defined as no emesis and no rescue regimen during 5 days of HEC. Secondary endpoints were overall complete protection (CP; CR+nausea score < 25 mm) and total control (TC; CR+nausea score < 5 mm). Quality of life was assessed by Functional Living Index Emesis (FLIE) questionnaire on D0 and D6.

Results:
A total of 279 patients receiving RAD (n=137) or PAD (n=142) were evaluated. Overall CR rates in RAD and PAD recipients were 81.8% and 79.6% (risk difference [RD], 2.2%; 95% confidence interval [CI], −7.1 to 11.4), respectively. Overall CP and TC rates for RAD and PAD were 56.2% and 58.5% (RD, −2.3%; 95% CI, −13.9 to 9.4) and 47.5% vs. 43.7% (RD, 3.8%; 95% CI, −7.9 to 15.5), respectively. FLIE total score ≥ 108 (no impact on daily life) was comparable between RAD and PAD (73.9% vs. 73.4%, respectively). Adverse events were similar between the two groups.

Conclusion:
In all aspects of efficacy, safety and QOL, RAD is non-inferior to PAD for the control of CINV in cancer patients receiving HEC.
Keimyung Author(s)(Kor)
박건욱
김진영
Publisher
School of Medicine (의과대학)
Citation
Jin Hyoung Kang et al. (2020). Ramosetron versus Palonosetron in Combination with Aprepitant and Dexamethasone for the Control of Highly-Emetogenic Chemotherapy-Induced Nausea and Vomiting. Cancer Research and Treatment, 52(3), 907–916. doi: 10.4143/crt.2019.713
Type
Article
ISSN
2005-9256
Source
https://www.e-crt.org/journal/view.php?number=3082
DOI
10.4143/crt.2019.713
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/42829
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
공개 및 라이선스
  • 공개 구분공개
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.